Is C4 Therapeutics, Inc. (CCCC) Overvalued?
We dive into why C4 Therapeutics, Inc. (CCCC) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Commentary & Analysis
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 6.69%
As of Thursday, August 13, C4 Therapeutics, Inc.’s CCCC share price has surged by 6.69%, which has investors questioning if this is right time to sell.Michael Rose
What You Need to Know About C4 Therapeutics, Inc.'s Q3 Earnings
C4 Therapeutics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (CCCC) missed or beat analyst's expectations.Jenna Brashear
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Up 5.17%
As of Tuesday, July 21, C4 Therapeutics, Inc.’s CCCC share price has surged by 5.17%, which has investors questioning if this is right time to sell.Jenna Brashear
Why C4 Therapeutics, Inc.’s (CCCC) Stock Is Down 5.28%
As of Monday, July 20, C4 Therapeutics, Inc.’s CCCC share price has dipped by 5.28%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $406.0 | $269.5 | 35% |
|
| Shares Out (Mil) | 130.7 | 54.2 | 68% |
|
| Institutional Ownership | 98.8% | 93.0% | 82% |
|
| Float (Mil) | 94.5 | 42.1 | 60% |
|
| Beta | 2.95 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 1,684 | 609 | 78% |
|
| Price Change (52-week) |
(0.6%) | 54.5% | 50% |
|
| Growth | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.6% | 13.6% | 22% |
|
| Net Income (5yr) | (9.6%) | (10.1%) | 29% |
|
| EPS (5yr) | 26.3% | 15.4% | 77 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (50.9%) | (15.6%) | 7% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.223) | ($0.885) | ($0.998) | |
| Month Ago EPS | ($0.223) | ($0.885) | ($0.998) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.253) | ($0.956) | ($1.040) | |
| Year/Year Chg | 23.2% | (30.1%) | (2.5%) | |
| Financials | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $35 | $37 | 17% |
|
| Net Income (TTM) (Mil) | ($101) | ($43) | 11% |
|
| EPS (TTM) | ($0.908) | ($1.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($85) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $2 | 44% |
|
| Long-Term Debt (Q1) (Mil) | $50 | $4 | 39% |
|
| Enterprise Value (Q1) (Mil) | $174 | $175 | 25% |
|
| Valuation | CCCC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.64 | 2.60 | 44% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CCCC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 86.3% | 68.9% | 92% |
|
| Net Margin | (289.4%) | (72.5%) | 3% |
|
| ROA | (30.9%) | (47.4%) | 16% |
|
| ROE | (48.1%) | (54.9%) | 16% |
|
| Liabilities to Assets | 31.2% | 29.3% | 22% |
|
| F-Score | 5 | 3 | 50% |
|
C4 Therapeutics, Inc. did not pass any screens on 9/21/2026.
